Deutsches Krebsforschungszentrum

Deutsches Krebsforschungszentrum (DKFZ), doing business as Dkfz, is a German non-profit organization and foundation focused on cancer research. Registered to receive awards from the U.S. federal government since 2006, DKFZ provides a wide range of cancer-related testing, data analysis, and research services to U.S. federal agencies. The organization's expertise spans multiple areas of cancer research, including molecular pathogenesis, diagnostic approaches, and therapeutic developments, with particular emphasis on hereditary colorectal cancer and immunoprevention. DKFZ has established itself as a key collaborator in international cancer research efforts, working closely with various U.S. federal agencies and academic institutions.

Through federal contract awards, DKFZ has provided specialized services primarily to components of the Department of Health and Human Services, such as the National Institutes of Health and the National Cancer Institute, as well as the Department of Defense's Defense Health Agency. These services include multiplex serology testing of antigens and plasma samples, data collection, harmonization, and management related to cancer risk factors, and testing for relationships between infections and specific types of cancer. Notable contract work includes a $507,000 purchase order from the National Cancer Institute to test up to 13,000 samples from the Anchor Trial using a multiplex serology assay, and a $397,800 contract for testing various elements related to cancer research, leveraging DKFZ's expertise in molecular pathogenesis and diagnostic approaches. The organization has also been involved in developing cancer screening methods and therapies. Most of these contract awards did not have set-aside designations, indicating open competition for the work.

DKFZ has also received significant federal grant funding, often as a sub-awardee collaborating with prime grantee institutions such as Weill Cornell Medical College, Duke University, and the University of California San Francisco. These grants, awarded by agencies including the National Institutes of Health, Department of the Army, and Defense Health Agency, have supported a wide array of research projects. Notable examples include early ovarian cancer detection, analyzing circulating compounds and breast cancer survival, examining Helicobacter pylori antibodies across cohorts, developing intensity modulated proton therapy treatment planning techniques, testing neoantigen vaccines for colorectal cancer prevention, and performing genetic interaction mapping and pathway analysis. In these grant-funded efforts, DKFZ has provided experimental testing, data analysis, computational modeling, project management, and subject matter expertise, often contributing to multi-year, multi-million dollar research initiatives in collaboration with U.S.-based research institutions.